BioCentury | Sep 5, 2016
Clinical News

CRLX101: Phase II data

...of care (SOC). SOC included Avastin, Nexavar sorafenib, Sutent sunitinib, Inlyta axitinib, Votrient pazopanib, Torisel temsirolimus...
BioCentury | May 9, 2016
Company News

J&J sales and marketing update

...that covalently binds to cysteine residue 481 adds major benefit in patients for whom Torisel temsirolimus...
BioCentury | Mar 15, 2016
Clinical News

ASCO starts enrolling TAPUR trial

...axitinib , Bosulif bosutinib , Xalkori crizotinib , Ibrance palbociclib , Sutent sunitinib and Torisel temsirolimus...
BioCentury | Dec 14, 2015
Clinical News

Imbruvica ibrutinib: Phase III data

...560 mg oral Imbruvica met the primary endpoint of improving median PFS vs. IV Torisel temsirolimus...
...0.32, 0.58, p<0.0001). Imbruvica led to a 2-year PFS rate of 41% vs. 7% for Torisel...
...3 months for Torisel. Median OS was not reached with Imbruvica vs. 21.3 months for Torisel...
BioCentury | Sep 21, 2015
Regulation

England's cancer problem

...refractory mantle cell lymphoma Nov-15 Under review, Dec 2016 pub date Rituxan +/- chemo; Torisel temsirolimus...
...Mar-15 Not reviewed Rituxan; cladribine Relapsed mantle cell lymphoma Mar-15 Not reviewed Rituxan +/- chemo; Torisel...
...+/- chemo; Zydelig Relapsed mantle cell non-Hodgkin's lymphoma (NHL) Nov-15 Not reviewed Rituxan +/- chemo; Torisel...
BioCentury | Mar 16, 2015
Strategy

Bru-te force

...Mid-2015 First line RAY Ph III Relapsed or refractory mantle cell lymphoma (MCL) Monotherapy Torisel temsirolimus...
BioCentury | Jan 5, 2015
Clinical News

Oral neratinib: Interim Phase II data

...I/II trial showed that once-daily 240 mg oral neratinib plus once-weekly 8 mg IV Torisel temsirolimus...
...Phase I portion of the trial identified once-daily 240 mg neratinib plus once-weekly 8 mg Torisel...
...cohort of the Phase II portion of the trial received once-daily 240 mg neratinib plus Torisel...
BioCentury | Dec 8, 2014
Clinical News

Oral neratinib: Phase II data

...II trial showed that once-daily 240 mg oral neratinib plus once-weekly 8 mg IV Torisel temsirolimus...
BioCentury | Aug 18, 2014
Clinical News

Selumetinib: Phase II data

...in median PFS, the primary endpoint, between twice-daily oral selumetinib as monotherapy and selumetinib plus temsirolimus...
...1.9 vs. 2.1 months). In a prespecified subgroup of patients with leiomyosarcoma (n=21), selumetinib plus temsirolimus...
...oncology indications (see BioCentury, Dec. 22, 2003). Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Torisel temsirolimus...
BioCentury | May 12, 2014
Clinical News

Imbruvica ibrutinib: Completed Phase III enrollment

...mg oral ibrutinib once daily in 21-day cycles vs. IV Torisel temsirolimus. Patients in the Torisel...
...a 2011 deal (see BioCentury, Dec. 12, 2011). Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Torisel...
Items per page:
1 - 10 of 112